F+FreeMedSite USMLELearn with clinical reasoning
SEPARATE VIVA EXTENSION

Denosumab inhibition of osteoclast differentiation

Follow-up oral questions and concise, clinically defensible model answers. Your MCQ remains open in its original tab.

← Return to original MCQ
EXAMINER FOLLOW-UP 1

Where is RANK expressed?

On osteoclast precursors and osteoclast-lineage cells.

EXAMINER FOLLOW-UP 2

What endogenous protein competes for RANKL?

Osteoprotegerin.

EXAMINER FOLLOW-UP 3

What is a major discontinuation risk?

Rapid rebound bone turnover with increased risk of multiple vertebral fractures.